Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial.
Journal: JAMA ophthalmology
Published: August 03, 2023
Prophylactic Ranibizumab to Prevent Neovascular Age-Related Macular Degeneration in Vulnerable Fellow Eyes: A Randomized Clinical Trial.
Journal: Ophthalmology. Retina
Published: January 23, 2022
Post-hoc analysis of single nucleotide polymorphism profile for eyes with vascularized pigment epithelial detachment due to ARMD.
Journal: European journal of ophthalmology
Published: June 25, 2020
Meticulous multimodal analysis of aflibercept therapy for submacular vascularized pigment epithelial detachment associated with neovascular AMD in a prospective case series, the EVEN study.
Journal: American journal of ophthalmology case reports
Published: February 21, 2020
Single nucleotide polymorphism profiles associated with three common phenotypes of advanced age-related macular degeneration.
Journal: Acta ophthalmologica
Published: December 18, 2019
Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial.
Journal: Ophthalmology
Published: February 02, 2019
Treatment outcomes of conventional or high-dose ranibizumab for vascularized pigment epithelial detachment based on lesion subtypes.
Journal: European journal of ophthalmology
Published: March 27, 2018
TYPE 1 VERSUS TYPE 3 NEOVASCULARIZATION IN PIGMENT EPITHELIAL DETACHMENTS ASSOCIATED WITH AGE-RELATED MACULAR DEGENERATION AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY: A Prospective Study.
Journal: Retina (Philadelphia, Pa.)
Published: December 23, 2016
Earlier therapeutic effects associated with high dose (2.0 mg) Ranibizumab for treatment of vascularized pigment epithelial detachments in age-related macular degeneration.
Journal: Eye (London, England)
Published: July 08, 2014
Prospective evaluation of the incidence and risk factors for the development of RPE tears after high- and low-dose ranibizumab therapy.
Journal: Retina (Philadelphia, Pa.)
Published: May 09, 2013
High-dose ranibizumab therapy for vascularized pigment epithelial detachment.
Journal: Eye (London, England)
Published: May 12, 2012
Showing 1-11 of 11
Last Updated: 09/26/2026